摘要
目的:探讨联检血清人附睾蛋白4(HE4)和CA125水平在卵巢癌诊断中的应用价值。方法:用ELISA测定47例卵巢癌患者、65例卵巢良性疾病患者和109例健康对照者血清HE4水平,同时测定CA125,并对结果进行比较分析。结果:卵巢癌组血清HE4、CA125水平均显著高于健康对照组,差异有统计学意义(P<0.01),HE4在早期卵巢癌(Ⅰ～Ⅱ期)阳性率高于CA125,两者联检可提高诊断卵巢癌的敏感性。结论:HE4是一种良好的预测早期卵巢癌的肿瘤标志物,其联合CA125的测定有助于卵巢癌的诊断。
Objective To investigate the diagnostic value of determination of serum human epididymis protein 4 （HE4） and CA125 levels in patients with ovarian cancer.Methods Serum HE4 （with ELISA） and CA125 （with CLIA） levels were determined in 47 patients with ovarian cancer,65 patients with benign ovarian disorders and 109 controls.Results The levels of HE4 and CA125 were significantly higher in ovarian cancer group than those in benign ovarian disease group and controls （all P 〈0.01） ,there were no significant differences between the levels in benign ovarian disease group and controls.The positive rate of HE4 was higher than that of CA125 in patients with early ovarian cancer.The combined determination of the two markers yielded the highest diagnostic sensitivity.Conclusion HE4 might be a good tumor biomarker in diagnosis early ovarian cancer combined determination of HE4 with CA125 would be more sensitive.
出处
《放射免疫学杂志》
CAS
2010年第5期564-565,共2页
Journal of Radioimmanology
